CVRx develops the BAROSTIM NEO, a baroreceptor neuromodulation device that delivers electrical pulses to carotid‑artery baroreceptors to restore autonomic balance and improve symptoms of heart failure. The BAROSTIM NEO is approved by the FDA for heart failure, has received FDA Breakthrough Device designation, and holds CE Marking for heart failure and resistant hypertension in the EEA. CVRx intends to commercialize BAROSTIM NEO in the United States and use recent financing proceeds to expand its U.S. footprint. The company emphasizes improving patient outcomes, quality of life, and overall cardiovascular health via its therapy. CVRx is headquartered near Minneapolis, Minnesota. CVRx develops BAROSTIM NEO, a second‑generation, minimally invasive implantable system that is CE‑marked for separate indications of heart failure and resistant hypertension. BAROSTIM NEO is commercially available in over 20 countries and the company holds an HDE approval for a legacy device in hypertension responders. CVRx is completing the BeAT‑HF Phase III pivotal clinical trial to evaluate BAROSTIM NEO’s safety and effectiveness in chronic heart failure and intends to use proceeds to support that trial and expand global commercial activities. The company cites positive prior randomized HOPE4HF trial results and published data supporting improvements in symptoms, function, and reduced hospitalization days. Founded in 2001 and headquartered in Minneapolis, Minnesota, CVRx markets its device internationally while pursuing U.S. regulatory approval through the ongoing pivotal trial. The recent financings provide near-term capital to advance clinical and commercial programs. CVRx was founded in 2001 and is headquartered in Minneapolis. The company has developed the second-generation Barostim neo, an implantable system designed to treat hypertension and heart failure. Barostim neo received CE marking for the treatment of hypertension in Europe. It is under clinical evaluation for the treatment of heart failure in Europe and the United States, and under clinical evaluation for hypertension in the United States. CVRx secured a $15M debt facility from Silicon Valley Bank and intends to use the funds to continue investing in market development and the clinical activities required to deliver Barostim Therapy. CVRx is a Minneapolis, MN-based medical device company founded in 2001 that developed Barostim neo, a medical device system designed to treat hypertension and heart failure. Barostim neo received CE marking for the treatment of hypertension in Europe and is under clinical evaluation for heart failure in Europe and the United States; it is also under clinical evaluation for hypertension in the United States. The company is led by President and CEO Nadim Yared and Executive Vice President and Chief Technology Officer Robert Kieval. CVRx closed an additional $12m in Series F financing, bringing total capital raised to $42m. Backers in the round included Ysios Capital, DaVita HealthCare Partners and others, and Josep Sanfeliu of Ysios Capital joined CVRx’s board of directors in conjunction with the funding. The company plans to use the capital to advance its clinical trials and expand its international commercial activities. CVRx, founded in 2001 and based in Minneapolis, develops the Barostim neo™, an implantable system designed to treat hypertension and heart failure. Barostim neo has received CE marking for the treatment of hypertension in Europe. The device is under clinical evaluation for the treatment of heart failure in Europe and the United States, and is also under clinical evaluation for the treatment of hypertension in the United States. CVRx is led by President and CEO Nadim Yared and Executive VP and CTO Robert Kieval. The company intends to use new funding to advance its clinical trials and to expand its international commercial activities. The article does not disclose revenue or user metrics.

Total raised

$184M

Funding rounds

6

Latest round

Equity

Latest activity

Jul 2020